|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients显示文摘 | Vermeuien PB Pawinski A | 1997 | British J of Cancer1997，76，2： | 1 |
| 2 | Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib显示文摘 | Dirix LY Ignacio J Nag S | 2008 | J Clin Oncol2008，26，8： | 1 |
| 3 | High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment显示文摘 | Kvinnsland S Anker G Dirix LY | 2000 | Eur J Cancer2000，36，8： | 1 |
| 4 | Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer:, resuits of a phase Ⅲ randomized double-blind trial 显示文摘 | Kaufmann M Bajetta E Dirix LY | 2000 | J Clin Oncol2000，18，7： | 1 |
| 5 | Neratinib,an irreversible ErbB receptor tyrosine kinase inhibitor,in patients with advanced ErbB2-positive breast cancer 显示文摘 | Burstein HJ Sun Y Dirix LY | 2010 | J Clin Oncol2010，28，8： | 1 |
| 6 | High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer whohad previously failed on tamoxifen treatment 显示文摘 | Kvinnsland S Anker G Dirix LY | 2000 | Eur J Cancer2000，36，8： | 1 |
| 7 | Phase III study of bevaci- zumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor re- ceptor 2-negative metastatic breast cancer 显示文摘 | Miles DW Chan A Dirix LY | 2010 | J Clin Oncol2010，28，20： | 1 |
| 8 | Neratinib, Anirrenersible erbb receptortyrosine kinase inhibitor, In patients with advanced erbb positive breast cancer 显示文摘 | Burstein HT Sun Y Dirix LY | 2010 | Journal of Clinical Oucology2010，28，8： | 1 |
| 9 | High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment显示文摘 | Kvinnsland S Anker G Dirix LY | 2000 | Eur J Cancer2000，36，8： | 1 |
| 10 | Gefitinib or piacebo in com- bination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase Ⅱ study 显示文摘 | Osborne CK Neven P Dirix LY | 2011 | Clin Cancer Res2011，17，5： | 1 |
| 11 | Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer显示文摘 | Dirix LY Salgado R Weytjens R | 2002 | Br J Cancer2002，86，3： | 1 |
| 12 | Plasma fibrin Ddimer levels correlate with tumour volume,progression rate and survival in patients withmetastatic breast cancer显示文摘 | Dirix LY Salgado R Weytjens R | 2012 | Br J Cancer2012，86，3： | 1 |
| 13 | Phase IQ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer显示文摘 | Miles DW Chan A Dirix LY | 2010 | J Clin Onco12010，28，20： | 1 |
| 14 | Biomarker results from the AVADO Phase 3 trial of first - line bevacizumab plus docetaxel for HER - 2 - negative metastatic breast cancer显示文摘 | Miles DW De Haas SL Dirix LY | 2013 | Br J Cancer2013，108，5： | 1 |
| 15 | Exemestane is superior to megestrol acetate after tamoxifen failure in postmenop ausal women with advanced breast cancer: results of a phase Ⅲ randomized double-blind trial显示文摘 | Kaufmann M Bajetta E Dirix LY | 2000 | J Clin Oncol2000，18，7： | 1 |
| 16 | Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2- positive breast cancer显示文摘 | BURSTEIN HJ SUN Y DIRIX LY | 2010 | J Clin Oneol2010，28，8： | 1 |
| 17 | Phase m study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2- negative metastatic breast cancer 显示文摘 | MILES DW CHAN A DIRIX LY | 2010 | J Clin Oncol2010，28，20： | 1 |
| 18 | High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment显示文摘 | Kvinnsland S Anker G Dirix LY | 2000 | Cur J Cancer2000，36，8： | 1 |
| 19 | Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer显示文摘 | Dirix LY Salgado R Weytjens R | 2002 | Br J Cancer2002，86，3： | 1 |
| 20 | Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer:results of a phase III randomized double-blind trial显示文摘 | BAJETTA E DIRIX LY | 2000 | J Clin Oncol2000，18，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员